Seminars in Hematology
Volume 45, Issue 1 , Pages 23-30 , January 2008

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

References 

  1. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine (A new anticancer drug with effectiveness in acute myelogenous leukemia). Ann Intern Med. 1976;85:237–245
  2. Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ, et al. 5-Azacytidine in acute leukemia. Cancer. 1978;42:2111–2114
  3. Constantinides PG, Taylor SM, Jones PA. Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol. 1978;66:57–71
  4. Jones PA, Taylor SM. Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells. Nucleic Acids Res. 1981;9:2933–2947
  5. Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase (Use of 5-azacytosine-containing DNA). J Mol Biol. 1982;163:679–692
  6. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol. 2000;249:35–54
  7. Bird PA. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209–213
  8. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoetic malignancies. Blood Rev. 2006;20:1–13
  9. Fahrner JA, Eguchi S, German JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213–7218
  10. Teofili L, Martini M, Di Mario A, Rutella S, Urbano R, Luongo M, et al. Expression of p15(INK4B) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood. 2001;98:495–497
  11. Christman JK, Mendelsohn N, Herzog D, Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res. 1983;43:763–769
  12. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′deoxycydidine induces p21WAF expression by demethylation of p73 leading to apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683–695
  13. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107
  14. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429–2440
  15. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  16. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer. 2006;106:1794–1803
  17. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O’Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57
  18. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exper Hematol. 2007;35:263–273
  19. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res. 2005;11:3862–3868
  20. Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, et al. Oral decitabine reactivates expression of the methylated g-globin gene in Papio anubis. Am J Hematol. 2007;82:981–985
  21. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res. 2001;265:195–202
  22. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell. 2003;4:13–18
  23. Rosato RR, Grant S. Histone deacetylase inhibitors: Insights into mechanisms of lethality. Expert Opin Ther Targets. 2005;9:809–824
  24. Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: From target to clinical trials. Expert Opin Investig Drugs. 2002;11:1695–1713
  25. Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002;8:963–970
  26. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrant B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266–1269
  27. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781–2790
  28. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959–967
  29. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, et al. Cardiac Studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762–3773
  30. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247–1252
  31. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al: Phase I study of the histone deacetylase inhibitor vorinostat in patients with advanced leukemias and myelodysplastic syndromes. Blood (in press)
  32. Marks PA. SAHA as an anticancer agent. Oncogene. 2007;26:1351–1356
  33. Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005;104:101–109
  34. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Ann Hematol. 2005;84:61–66
  35. Gore SD, Baylin SB, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369
  36. Soriano AO, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–2308
  37. Oki Y, Aoki E, Issa JP. Decitabine—Bedside to bench. Crit Rev Oncol. 2007;61:140–152
  38. Yang AS, Doshi KD, Choi SW, Mason JB, Manari RK, Gharybian V, et al. DNA methylation changes after 5-aza-2′deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66:5495–5503
  39. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol. 1991;37:100–104
  40. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavorable myelodysplastic syndromes. Leukemia. 1993;7(suppl 1):30–35
  41. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635–1640
  42. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(suppl 1):21–29
  43. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11:1–5
  44. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279
  45. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884–3891

 This work was supported in part by National Cancer Institute Grant No. K24 CA111717.

PII: S0037-1963(07)00164-3

doi: 10.1053/j.seminhematol.2007.11.007

Seminars in Hematology
Volume 45, Issue 1 , Pages 23-30 , January 2008

Article Tools

* Image Usage & Resolution